- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 25, 2023
Highlights
- Market Cap
- $433.35K
- Enterprise Value
- $1.08B
- EPS (TTM)
- $1.66
- PE Ratio
- 0.01
- Total Revenue (TTM)
- $696.38M
- Gross Profit (TTM)
- $256.69M
- EBITDA (TTM)
- $45.89M
- Year Range
- $0.01 - $0.02
- ROA (TTM)
- 0.49%
- ROE (TTM)
- 1.29%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CDTTW Performance Chart
Conduit Pharmaceuticals Inc. (CDTTW) is up 100.0% since the beginning of the year. At $0 per share, CDTTW is trading 49.3% below its 52-week high of $0.
Loading charts...
Returns By Period
Conduit Pharmaceuticals Inc. (CDTTW) has returned 100.00% so far this year and 10.00% over the past 12 months.
Conduit Pharmaceuticals Inc.
- 1D
- -12.77%
- 1M
- -21.43%
- YTD
- 100.00%
- 6M
- 17.02%
- 1Y
- 10.00%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
CDTTW Monthly Returns History
Based on dividend-adjusted daily data since Sep 25, 2023, CDTTW's average daily return is +2.08%, while the average monthly return is +10.65%. At this rate, an investment would double in approximately 0.6 years.
Historically, 50% of months were positive and 50% were negative. The best month was Nov 2023 with a return of +266.7%, while the worst month was Dec 2024 at -70.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, CDTTW closed higher 29% of trading days. The best single day was Nov 29, 2023 with a return of +421.3%, while the worst single day was Apr 24, 2024 at -59.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.55% | 28.57% | 2.47% | -9.64% | 164.00% | -44.44% | 100.00% | ||||||
| 2025 | 122.03% | -4.58% | -26.40% | -17.39% | 40.79% | 1.87% | 8.26% | 27.12% | -29.57% | 1.29% | 18.69% | -56.69% | -6.78% |
| 2024 | -13.28% | 16.47% | -14.29% | 50.00% | -55.44% | -61.35% | 29.68% | -52.74% | 24.21% | -27.12% | 132.56% | -70.50% | -91.49% |
| 2023 | -33.33% | -33.33% | 266.67% | -37.00% | 2.67% |
Benchmark Metrics
Conduit Pharmaceuticals Inc. has an annualized alpha of 14331.13%, beta of 1.07, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 25, 2023.
- This stock participated in 400.03% of S&P 500 Index downside but only 302.61% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14,331.13%
- Beta
- 1.07
- R²
- 0.00
- Upside Capture
- 302.61%
- Downside Capture
- 400.03%
Return for Risk
Risk / Return Rank
CDTTW ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Conduit Pharmaceuticals Inc. (CDTTW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CDTTW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.74 | ||
| Sortino ratioReturn per unit of downside risk | -0.09 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.32 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 0.14 | 2.46 | -2.32 |
| Martin ratioReturn relative to average drawdown | 0.22 | 10.92 | -10.70 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Conduit Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Conduit Pharmaceuticals Inc. was 96.07%, occurring on Dec 31, 2025. The portfolio has not yet recovered.
The current Conduit Pharmaceuticals Inc. drawdown is 92.14%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -96.07%Dec 2025 | 1y 10mo | — | 2y 3moFeb 2024 - now |
2023 bear market2023 | -70.31%Oct 2023 | 29d | 1mo 5d | 2mo 4dSep 2023 - Nov 2023 |
2023 bear market2023 | -54.45%Dec 2023 | 16d | 16d | 1mo 2dDec 2023 - Jan 2024 |
2024 bear market2024 | -45.45%Feb 2024 | 27d | 17d | 1mo 14dJan 2024 - Feb 2024 |
Drawdown Indicators
| CDTTW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.07% | -56.78% | -39.29% |
Max Drawdown (1Y)Largest decline over 1 year | -71.79% | -9.10% | -62.69% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -92.14% | -3.21% | -88.93% |
Average DrawdownAverage peak-to-trough decline | -79.43% | -10.71% | -68.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.30% | 2.04% | +44.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Conduit Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Conduit Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CDTTW, comparing it with other companies in the Biotechnology industry. Currently, CDTTW has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CDTTW relative to other companies in the Biotechnology industry. Currently, CDTTW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CDTTW in comparison with other companies in the Biotechnology industry. Currently, CDTTW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CDTTW
Add Conduit Pharmaceuticals Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CDTTW